112828-00-9

Basic information

• Product Name: Calcipotriene
• Synonyms: CALCIPOTRIOL;(1s,3s,5z)-5-[(2e)-2-[(1r,3ar,7ar)-1-[(e,2s)-5-cyclopropyl-5-hydroxy-pent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol;(1r,3s,5z)-5-[(2e)-2-[1-[(e,2r,5r)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol;24-CYCLOPROPYL-(1ALPHA,3BETA,5Z,7E,22E,24S)-9,10-SECOCHOLA-5,7,10(19),22-TETRAENE-1,3,24-TRIOL;Calcipotriene;Calcipotriene/calcipotriol
• CAS NO: 112828-00-9
• Molecular Formula: C27H40O3
• Molecular Weight: 412.6
• EINECS: 1806241-263-5
• Product Categories: API
• Mol File: 112828-00-9.mol
• Article Data: 0

Chemical Properties

• Melting Point: 166-168℃
• Boiling Point: 582 °C at 760 mmHg
• Flash Point: 250.6 °C
• Appearance: WHITE
• Density: 1.12 g/cm³
• Vapor Pressure: 5.74E-16mmHg at 25°C
• Refractive Index: 1.579
• CAS DataBase Reference: Calcipotriene(CAS DataBase Reference)
• NIST Chemistry Reference: Calcipotriene(112828-00-9)
• EPA Substance Registry System: Calcipotriene(112828-00-9)

Safety Data

• Hazardous Substances Data: 112828-00-9(Hazardous Substances Data)

Usage

Uses

Antipsoriatic.

Indications

Calcipotriene (calcipotriol) is a synthetic vitamin D3 derivative that is useful for the treatment of patients with moderate plaque psoriasis. Its effects are comparable with those of class II topical steroids, without the associated adverse effects. Its mechanism of action involves both induction of terminal differentiation of keratinocytes and inhibition of keratinocyte production. It should be applied to the face with care, as this region is more susceptible to irritation, burning, and itching, as seen in approximately 10% of patients. Other adverse effects include erythema, peeling, xerosis, dermatitis, or worsening psoriasis in 1% to 10% of patients. Fewer than 1% of patients experience hypercalcemia, atrophy, hyperpigmentation, or folliculitis. Allergic contact dermatitis to calcipotriene has been reported. Most patients demonstrate improvement after 2 weeks; 70% of patients improve after 8 weeks, with 10% showing complete clearing. It should be avoided in patients with documented impairment in calcium metabolism, hypercalcemia, vitamin D toxicity, or history of renal stones. Calcipotriene may be used as an adjuvant with psoralens plus ultraviolet A (PUVA) and ultraviolet B (UVB). Pretreatment with or subsequent addition of calcipotriol to PUVA reduces the cumulative doses of UVA needed to achieve >75% reduction in severity and distribution of psoriasis.

Brand name

Dovonex (Leo).

InChI:InChI=1/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24?,25-,26+,27-/m1/s1